Aligning Incentives to Fight Neglected Diseases

Chris Colwell and I recently wrote BIO white paper titled “Ideas to Encourage Innovation for Diseases Without a Market”
Here’s the problem it explores: on average a drug or biologic costs about $1.2 billion to bring to market. But when a disease mainly affects the developing world (e.g., leishmaniasis or dengue haemorrhagic  fever ), it’s difficult [...]

All the buzz about biotech

The convention hosted a whirlwind of activity and major announcements - and now the work begins to prove the exponential effect that the event inspires. The majority of media coverage focused on states competing for biotech attention and building up their life sciences community to make them more attractive for companies, investors and others looking to [...]